The Food and Drug Administration on Sept. 25 approved a new therapy for advanced breast cancer, based on data from a phase 3 clinical trial.
Regulators said in a statement that they approved imlunestrant, also known as Inluriyo, from Eli Lilly.
FDA Approves New Therapy for Advanced Breast Cancer
The Food and Drug Administration approved a therapy from Eli Lilly.
Eli Lilly's headquarters in Indianapolis, Ind., in an undated file photograph. Scott Olson/Getty Images
Zachary Stieber
Senior Reporter
Zachary Stieber is a senior reporter for The Epoch Times based in Maryland. He covers U.S. and world news. Contact Zachary at [email protected]
Author’s Selected Articles
